Effects of adjunctive Acetazolamide therapy in patients of Obstructive Sleep Apnea

Phase 2

Completed

• Conditions: Health Condition 1: G473- Sleep apnea

• Registration Number: CTRI/2023/07/054889
• Lead Sponsor: Anurag Ambikaprasad Tripathi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-05-31
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 95

Inclusion Criteria

Patients of Obstructive Sleep Apnea with AHI of 5 and more with no active infections in 4 weeks prior to recruitment with Body Mass Index of at least 20 kg/m2 and Epsworth Sleepiness Score of at least 6.

Exclusion Criteria

Refusal to participate

Refusal of PAP therapy

Allergy to sulfonamides

Central sleep apnoea syndromes, dominant Cheyne-Stokes respiration, or significant sleep disorders including periodic limb movements or parasomnia

Patients who had received OSA treatment within 4 weeks of the baseline visit

Unstable pulmonary or gastrointestinal disease,

Severe congestive heart failure, a history of life-threatening arrhythmias, severe cardiomyopathy

Significant chronic kidney disease or hepatic disease

Potassium levels less than 3 mmol/L

Sodium levels less than 125 mEq/L

History of mental illness or those on Amphetamines

Drug or alcohol abuse, use of sedatives, severe cognitive impairment or

Concurrent oncological diseases.

Seizure disorders

Prior to the treatment with AZM it will be confirmed that no obvious causes of upper airways obstruction have been detected in the nose, throat or lower jaw by examinations performed at the Department of Otorhinolaryngology.

Study & Design

• Study Type: Interventional
• Study Design: Not specified